Skip to main content
. 2022 Jan 24;10(2):177. doi: 10.3390/vaccines10020177

Figure 3.

Figure 3

Anti-SARS-CoV-2 spike protein antibody levels of all participants according to the time since the most recent dose of the BNT162b2 vaccine was administered. The horizontal line indicates the median levels among participants without infection tested 94 to 109 days (2425 AU/mL) and 199 to 212 days (813 AU/mL) after the second vaccination. Infection includes PCR positive results and/or anti-N antibody positive results.